Core Insights - BioVersys AG has entered into an exclusive collaboration and license agreement with Hackensack Meridian Health (HMH) to develop ansamycin drug candidates targeting multi-drug resistant (MDR) bacteria [1][5] - The partnership aims to enhance BioVersys' Ansamycin Chemistry platform and advance the development of new antimicrobial agents for treating non-tuberculous mycobacterial (NTM) diseases [3][5] Company Overview - BioVersys AG is a clinical stage biopharmaceutical company focused on developing novel antibacterial products for serious infections caused by MDR bacteria [11] - The company utilizes two internal technology platforms, TRIC and Ansamycin Chemistry, to create candidates that can overcome resistance mechanisms and address unmet medical needs in antimicrobial treatments [11] Collaboration Details - The collaboration with HMH will involve joint profiling and development of ansamycin candidates, with HMH eligible for upfront payments and royalties on future sales [1] - HMH's Center for Discovery and Innovation (CDI) will contribute advanced lead molecules developed in collaboration with the University of Minnesota, enhancing BioVersys' existing platform [3][5] Market Context - Non-tuberculous mycobacteria (NTM) infections are a significant health issue, particularly affecting individuals with chronic lung conditions such as cystic fibrosis and chronic obstructive pulmonary disease (COPD) [6][7] - The incidence of NTM infections among cystic fibrosis patients has increased from 3.3% to 22.6%, highlighting the growing need for effective treatments [6] Research and Development - The BV500 program, part of the collaboration, focuses on developing advanced lead molecules for NTM infections, with current cure rates for NTM lung disease as low as 30-50% [7] - The partnership emphasizes the importance of collaborative research in addressing antimicrobial resistance (AMR), a major global health threat [7]

As filed with the U.S. Securities and Exchange Commission on February 4, 2026. Registration No. 333-292664 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO.1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ________________________________________ Lakewood-Amedex Biotherapeutics Inc. (Exact Name of Registrant as Specified in its Charter) ________________________________________ | Nevada | 2834 | 20-5274304 | | --- | --- | --- | | (State or Other Jurisdi ...

Core Viewpoint - The launch of Cumberland's Vibativ (telavancin) injection in Saudi Arabia represents a significant advancement in the treatment of serious infections, particularly those caused by multidrug-resistant bacteria, addressing a critical need in the region [2][4][6]. Company Overview - Tabuk Pharmaceutical Manufacturing Company, a subsidiary of Astra Industrial Group, is a leading pharmaceutical company in the Middle East, responsible for the registration and promotion of Vibativ in Saudi Arabia and other Middle Eastern countries [2][11]. - Cumberland Pharmaceuticals Inc. is a biopharmaceutical company based in Tennessee, focused on developing and commercializing unique products for hospital acute care, gastroenterology, and oncology [12]. Product Details - Vibativ is an FDA-approved injectable antibiotic designed to treat hospital-acquired and ventilator-associated pneumonia, as well as complicated skin infections caused by Gram-positive bacteria, including MRSA and MSSA [3][9]. - The drug is administered intravenously with once-daily dosing and does not require therapeutic drug monitoring, which reduces healthcare professionals' exposure to patients [3][4]. - Vibativ was specifically engineered to combat drug-resistant bacteria, enhancing its efficacy against difficult-to-treat infections [5][6]. Market Context - The global rise in antimicrobial resistance (AMR) poses a significant threat to public health, making Vibativ a crucial addition to the anti-infective portfolio in the Middle East [4][5]. - Studies indicate that Vibativ maintains its potency against multidrug-resistant bacteria, demonstrating higher cure rates compared to vancomycin in treating Gram-positive infections [9][10]. Strategic Importance - The partnership between Tabuk and Cumberland aims to expand the reach of Vibativ, ensuring that it is accessible to patients in Saudi Arabia, thereby addressing urgent healthcare needs in the region [6][11].